[go: up one dir, main page]

WO2020080871A3 - Biomarker composition for determining cancer drug responsiveness, method for determining cancer drug responsiveness using biomarker composition, and diagnostic chip for detecting biomarker composition for determining cancer drug responsiveness - Google Patents

Biomarker composition for determining cancer drug responsiveness, method for determining cancer drug responsiveness using biomarker composition, and diagnostic chip for detecting biomarker composition for determining cancer drug responsiveness Download PDF

Info

Publication number
WO2020080871A3
WO2020080871A3 PCT/KR2019/013717 KR2019013717W WO2020080871A3 WO 2020080871 A3 WO2020080871 A3 WO 2020080871A3 KR 2019013717 W KR2019013717 W KR 2019013717W WO 2020080871 A3 WO2020080871 A3 WO 2020080871A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer drug
biomarker composition
responsiveness
determining cancer
drug responsiveness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2019/013717
Other languages
French (fr)
Korean (ko)
Other versions
WO2020080871A9 (en
WO2020080871A2 (en
Inventor
정종선
이선호
홍종희
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntekabio Inc
Original Assignee
Syntekabio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190096410A external-priority patent/KR20200044677A/en
Application filed by Syntekabio Inc filed Critical Syntekabio Inc
Publication of WO2020080871A2 publication Critical patent/WO2020080871A2/en
Publication of WO2020080871A3 publication Critical patent/WO2020080871A3/en
Publication of WO2020080871A9 publication Critical patent/WO2020080871A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a biomarker composition for determining the responsiveness of a discovered cancer drug by using genetic biomarker labeling scan (GBLscan), which is a drug indication and responsiveness prediction system and method, as a new learning model capable of reliably predicting the responsiveness of a drug by performing coupling analysis on a molecular profile of the drug after transforming specific genetic variation fingerprints related to diseases including cancer into a haplotype having functional information, a method for determining cancer drug responsiveness using the biomarker composition, and a diagnostic chip for detecting a biomarker composition for determining cancer drug responsiveness.
PCT/KR2019/013717 2018-10-18 2019-10-18 Biomarker composition for determining cancer drug responsiveness, method for determining cancer drug responsiveness using biomarker composition, and diagnostic chip for detecting biomarker composition for determining cancer drug responsiveness Ceased WO2020080871A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR10-2018-0124512 2018-10-18
KR20180124512 2018-10-18
KR1020190096410A KR20200044677A (en) 2018-10-18 2019-08-07 Bio-Marker for Prediction of Drug Sensitivity, Estimation Method for Prediction of Drug Sensitivity and Diagnosing Chip for Prediction of Drug Sensitivity
KR10-2019-0096410 2019-08-07
KR1020190098165A KR20200054058A (en) 2018-10-18 2019-08-12 Bio-Marker Composition for Prediction of Drug Sensitivity, Estimation Method for Prediction of Drug Sensitivity using Bio-Marker Composition and Diagnosing Chip for Detection of Bio-Marker Composition for Prediction of Drug Sensitivity
KR10-2019-0098165 2019-08-12
KR10-2019-0098492 2019-08-13
KR1020190098492A KR20200054059A (en) 2018-10-18 2019-08-13 Bio-Marker Composition for Prediction of Drug Sensitivity, Estimation Method for Prediction of Drug Sensitivity using Bio-Marker Composition and Diagnosing Chip for Detection of Bio-Marker Composition for Prediction of Drug Sensitivity

Publications (3)

Publication Number Publication Date
WO2020080871A2 WO2020080871A2 (en) 2020-04-23
WO2020080871A3 true WO2020080871A3 (en) 2020-08-06
WO2020080871A9 WO2020080871A9 (en) 2020-09-24

Family

ID=70283510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/013717 Ceased WO2020080871A2 (en) 2018-10-18 2019-10-18 Biomarker composition for determining cancer drug responsiveness, method for determining cancer drug responsiveness using biomarker composition, and diagnostic chip for detecting biomarker composition for determining cancer drug responsiveness

Country Status (1)

Country Link
WO (1) WO2020080871A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113652486B (en) * 2021-09-13 2023-02-03 新疆医科大学第四附属医院 Colorectal cancer treatment prognosis biomarker and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070031894A (en) * 2004-03-31 2007-03-20 더 제너럴 하스피탈 코포레이션 How to determine cancer's responsiveness to treatments that target epidermal growth factor receptors
US20080131885A1 (en) * 2006-03-31 2008-06-05 Memorial Sloan Kettering Cancer Center Biomarkers for cancer treatment
US20090298701A1 (en) * 2008-05-14 2009-12-03 Baker Joffre B Predictors of patient response to treatment with egf receptor inhibitors
US20100240665A1 (en) * 2008-10-20 2010-09-23 The Regents Of The University Of Colorado Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2669682A1 (en) * 2012-05-31 2013-12-04 Heinrich-Heine-Universität Düsseldorf Novel prognostic and predictive biomarkers (tumor markers) for human breast cancer
US20160024589A1 (en) * 2013-03-15 2016-01-28 The Broad Institute, Inc. Methods of identifying responses to map kinase inhibition therapy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070031894A (en) * 2004-03-31 2007-03-20 더 제너럴 하스피탈 코포레이션 How to determine cancer's responsiveness to treatments that target epidermal growth factor receptors
US20080131885A1 (en) * 2006-03-31 2008-06-05 Memorial Sloan Kettering Cancer Center Biomarkers for cancer treatment
US20090298701A1 (en) * 2008-05-14 2009-12-03 Baker Joffre B Predictors of patient response to treatment with egf receptor inhibitors
US20100240665A1 (en) * 2008-10-20 2010-09-23 The Regents Of The University Of Colorado Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2669682A1 (en) * 2012-05-31 2013-12-04 Heinrich-Heine-Universität Düsseldorf Novel prognostic and predictive biomarkers (tumor markers) for human breast cancer
US20160024589A1 (en) * 2013-03-15 2016-01-28 The Broad Institute, Inc. Methods of identifying responses to map kinase inhibition therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Table of Pharmacogenomic Biomarkers in Drug Labeling", WWW.FDA.GOV, June 2018 (2018-06-01), XP055727919, Retrieved from the Internet <URL:https://www.fda.gov/media/107901/download> *
BIGNUCOLO, A.: "Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 18, no. 7, 14 July 2017 (2017-07-14), pages 1522, DOI: 10.3390/ijms18071522 *

Also Published As

Publication number Publication date
WO2020080871A9 (en) 2020-09-24
WO2020080871A2 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
WO2005095644A3 (en) Method for recognizing signatures in complex gene expression profiles
WO2007117444A3 (en) Protein detection by aptamers
BR112012010108A2 (en) methods for aiding diagnosis and monitoring the progression or regression of computer readable irritable bowel syndrome; and a system for classifying whether a serum or blood sample from an individual is associated with irritable bowel syndrome.
WO2017055487A3 (en) A METHOD FOR DIAGNOSING A DISEASE BY DETECTION OF circRNA IN BODILY FLUIDS
US11312999B2 (en) Set of genes for molecular classifying of medulloblastoma and use thereof
WO2004092734A3 (en) Novel approach to molecular diagnosis of human papilloma virus-related diseases
WO2012122236A3 (en) Method and system to detect and diagnose alzheimer&#39;s disease
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2012112315A2 (en) Methods for diagnosis of kawasaki disease
RU2017101354A (en) KIT OR DEVICE FOR DETECTING LUNG CANCER AND DETECTION METHOD
BRPI1008957B8 (en) method for simultaneous detection of a plurality of target nucleic acids performed by an integrated real-time target nucleic acid analysis system
DK1889059T3 (en) Method for Enhanced Immunoassay
WO2008100352A3 (en) Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis
WO2009026381A3 (en) Method, computer program product and system for individual assessment of alcohol sensitivity
WO2007133586A3 (en) Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets
O'Bryant et al. Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study
US11782065B2 (en) Kits and methods for prediction and treatment of preeclampsia
ATE554389T1 (en) APEX AS A MARKER FOR LUNG CANCER
WO2019055661A8 (en) Preeclampsia biomarkers and related systems and methods
WO2007030571A3 (en) Identification of targets and development of reagents for testing and molecular imaging of human disease
EP4220171A3 (en) Markers for endometrial cancer
WO2020080871A3 (en) Biomarker composition for determining cancer drug responsiveness, method for determining cancer drug responsiveness using biomarker composition, and diagnostic chip for detecting biomarker composition for determining cancer drug responsiveness
WO2008003024A3 (en) Method and composition for diagnosing endometrial cancer
SG11201811433TA (en) Mmp1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method
WO2019089858A3 (en) Methods of assessing or monitoring a response to a cell therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19874536

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19874536

Country of ref document: EP

Kind code of ref document: A2